Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients

Table 1 Clinical characteristics of patients with chronic hepatitis C virus infection

Baseline characteristics	Non-SVR (n = 246)	SVR (n = 377)	P-value
Female	85 (34.6%)	128 (34.0%)	0.88
Age (years),	51.9 ± 8.4	50.0 ± 10.1	0.01
Body mass index (kg/m²)	24.6 ± 3.4	24.5 ± 3.5	0.71
Alcohol drinking	138 (68.7%)	155 (62.5%)	0.17
Diabetes mellitus	51 (25.5%)	55 (22.5%)	0.47
Genotype
1	131 (53.3%)	147 (39.0%)	<0.005
2	0	1 (0.3%)
3	101 (41.1%)	186 (49.3%)
6	14 (5.7%)	43 (11.4%)
Pre-treatment HCV-RNA (IU/ml)	6.02 ± 0.60	5.81 ± 0.88	0.003
Pre-treatment ALT level (U/L)	106.2 ± 158.3	102.5 ± 75.8	0.98
Pre-treatment AST level (U/L)	87.3 ± 130.2	73.4 ± 52.1	0.046
Advanced fibrosis (stage 2–4)	76 (51.0%)	73 (36.0%)	0.005
PEG-IFN alfa-2a	109 (55.6%)	145 (58.2%)	0.58

Data represent as n (%), mean ± SD. AST aspartate aminotransferase, ALT alanine aminotransferase, HCV RNA hepatitis C virus RNA, PEG-IFN pegylated interferon, SVR sustained virologic response, SD standard deviation

ISSN: 1471-230X